ArticleEndocrine oncology (Bristol, England)2025
Enucleation for pancreatic neuroendocrine tumors: short- and long-term outcomes in a forty-year single-center experience.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Procedure-specific morbidity and pathologic assessment after resection of small (≤20 mm) pancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgery plays a key role in the treatment of pancreatic neuroendocrine tumors (PanNETs). Enucleation combines a radical resection with the sparing of healthy pancreatic parenchyma. Methods: To evaluate short- and long-term outcomes of open enucleation for PanNETs, clinical records of patients operated on from 1979 to 2021 in our Pancreatic Surgical Unit were retrieved retrospectively. Results: Out of 246 PanNETs operated on, 62 (25%) patients underwent enucleation: 39 (63%) women and 23 (37%) men, averaging a mean of 55 (SD, 14) years. Pancreatic NETs were mostly insulinomas (65%), located in the head/uncinate process (61%), and grade 1 (55%), with a median size of 1.5 (IQR, 1.0-1.8) cm. Median operation time was 180 (IQR, 150-205) minutes, and median intraoperative blood loss was 100 (IQR, 20-200) mL. Pancreatic fistula (all grade B) occurred in ten (16%) patients. One (1.6%) reoperation was required for evisceration. Median hospital stay was 10 (IQR, 7-15) days. There was no postoperative mortality. Median follow-up was 153 (IQR, 91-278) months, with seven (11%) patients developing new onset diabetes; however, no exocrine insufficiency occurred. Fourteen (23%) patients died of unrelated causes after a mean overall survival of 219 (SD, 152) months. Conclusions: Enucleation of PanNETs resulted in excellent long-term results for both pancreatic function and oncological outcomes. In open surgery, postoperative morbidity is not negligible, but it does not affect patients' prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.